Wells Fargo
PHAS

Wells Fargo’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Wells Fargo’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,821
Closed – – 7907
2022
Q3 		$0 Buy
1,821
+14
+0.8% +$14 ﹤0.01% 7841
2022
Q2 		$1K Buy
1,807
+21
+1% +$20 ﹤0.01% 6704
2022
Q1 		$2K Buy
1,786
+1
+0.1% +$2 ﹤0.01% 6733
2021
Q4 		$5K Sell
1,785
-8,812
-83% -$26.6K ﹤0.01% 6724
2021
Q3 		$33K Buy
10,597
+8,793
+487% +$29.3K ﹤0.01% 5793
2021
Q2 		$7K Sell
1,804
-4,513
-71% -$15K ﹤0.01% 6256
2021
Q1 		$21K Sell
6,317
-18,475
-75% -$75K ﹤0.01% 6144
2020
Q4 		$83K Buy
24,792
+3,747
+18% +$13.4K ﹤0.01% 5430
2020
Q3 		$74K Sell
21,045
-3,937
-16% -$15.9K ﹤0.01% 5371
2020
Q2 		$114K Buy
24,982
+8,150
+48% +$36.1K ﹤0.01% 5170
2020
Q1 		$55K Buy
16,832
+8,699
+107% +$39.8K ﹤0.01% 5305
2019
Q4 		$50K Sell
8,133
-13,881
-63% -$57.2K ﹤0.01% 5510
2019
Q3 		$92K Buy
22,014
+5,968
+37% +$47.6K ﹤0.01% 5355
2019
Q2 		$211K Buy
+16,046
New +$197K ﹤0.01% 4949

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo's PHAS Position: Q4 2022 in Review

Wells Fargo sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 1,821 shares.

Wells Fargo first reported a position in PHAS in Q2 2019 and held it in 14 quarters. The position peaked at $211K in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Wells Fargo reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Wells Fargo sold 1,821 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • Wells Fargo first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
  • Wells Fargo's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $211K in Q2 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Wells Fargo's 13F filing for Q4 2022, filed 13 Feb 2023.